ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Edgewise Therapeutics Inc

Edgewise Therapeutics Inc (EWTX)

19.43
1.15
(6.29%)
Closed July 05 4:00PM
19.43
0.02
(0.10%)
After Hours: 5:30PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
19.43
Bid
19.50
Ask
20.00
Volume
434,932
18.235 Day's Range 19.47
5.12 52 Week Range 21.60
Market Cap
Previous Close
18.28
Open
18.48
Last Trade
5
@
19.5
Last Trade Time
Financial Volume
$ 8,179,004
VWAP
18.8052
Average Volume (3m)
655,202
Shares Outstanding
93,398,767
Dividend Yield
-
PE Ratio
-18.10
Earnings Per Share (EPS)
-1.07
Revenue
-
Net Profit
-100.16M

About Edgewise Therapeutics Inc

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Edgewise Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EWTX. The last closing price for Edgewise Therapeutics was $18.28. Over the last year, Edgewise Therapeutics shares have traded in a share price range of $ 5.12 to $ 21.60.

Edgewise Therapeutics currently has 93,398,767 shares outstanding. The market capitalization of Edgewise Therapeutics is $1.71 billion. Edgewise Therapeutics has a price to earnings ratio (PE ratio) of -18.10.

EWTX Latest News

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare...

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker – – Positive interim topline data for DUNE trial of sevasemten...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.448.0044469149517.9919.8117.5183147618.90566692CS
42.0711.923963133617.3619.8115.8770590817.60356519CS
123.1319.202453987716.321.614.965520217.72333124CS
269.5195.86693548399.9221.6983723816.33568524CS
5211.93159.0666666677.521.65.1256639313.93191218CS
156-1-4.8947626040120.4324.35.1234183013.00360431CS
260-7.57-28.0370370372740.495.1233204413.82470181CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 4.785
(122.56%)
46.48M
SHOTWSafety Shot Inc
$ 0.33
(83.33%)
1.6k
QLGNQualigen Therapeutics Inc
$ 0.28
(59.64%)
244.69M
INVZWInnoviz Technologies Ltd
$ 0.2499
(51.91%)
17.79k
ZAPPZapp Electric Vehicles Group Ltd
$ 4.06
(49.26%)
50.34M
VEVVicinity Motor Corporation
$ 0.391
(-30.67%)
409.44k
SKYESkye Bioscience Inc
$ 5.495
(-26.34%)
354.28k
CLEUChina Liberal Education Holdings Ltd
$ 2.16
(-24.74%)
13.42M
JZXNJiuzi Holdings Inc
$ 2.60
(-23.53%)
57.7k
WHLRWheeler Real Estate Investment Trust Inc
$ 15.02
(-23.01%)
30.36k
MAXNMaxeon Solar Technologies Ltd
$ 0.2378
(36.98%)
520.76M
QLGNQualigen Therapeutics Inc
$ 0.28
(59.64%)
244.69M
NVDANVIDIA Corporation
$ 125.83
(-1.91%)
214.21M
TSLATesla Inc
$ 251.52
(2.08%)
154.53M
SIRISirius XM Holdings Inc
$ 3.715
(5.24%)
121.14M

EWTX Discussion

View Posts
Whalatane Whalatane 4 days ago
Piper Sandler analyst Yasmeen Rahimi maintains Edgewise Therapeutics ( EWTX ) with a Overweight and maintains $48 price target.

Kiwi
👍️0
Whalatane Whalatane 4 days ago
RMB. some HCM P1 data due late Aug / Sept ...
Kiwi
👍️0
Whalatane Whalatane 2 months ago
RMB. I think we are due for data from the LYNX trial
, Edgewise Therapeutics expects to report 3-month data from the Phase 2 LYNX trial for EDG-5506 in the second quarter of 2024. The LYNX trial is a Phase 2 dose-ranging study to evaluate the safety and efficacy of EDG-5506 in patients with Duchenne muscular dystrophy (DMD).

New high today

Kiwi
👍️0
Whalatane Whalatane 3 months ago
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target

I'm surprised stock didn't do better on recent P 2 data ...which was supposed to " de risk " their program

Kiwi
👍️0
Whalatane Whalatane 5 months ago
BOULDER, Colo., February 13, 2024--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
---------------
Kiwi
👍️0
Whalatane Whalatane 5 months ago
RMB. for what its worth ...both stocks I mentioned are now "technically " over bought ...so some pull back near term is likely
jmo
Kiwi
👍️0
Whalatane Whalatane 5 months ago
RMB. EWTX up 21 % in past week. ( since your post )
VERA ,,,which I think U saw me posting on at the AUPH board ...up 28%
Both I think at 52 wk highs

Usually I find it best to initiate small positions ...follow ..and then if the data still looks good , add on a pullback due to some unrelated event .
Both of these Co's have a lot of data coming out in 2024

Kiwi
👍️0
Monksdream Monksdream 5 months ago
EWTX new 52 week high
👍️0
Monksdream Monksdream 5 months ago
EWTX new 52 week high
👍️0
Whalatane Whalatane 5 months ago
Jonathan C. Fox, M.D., Ph.D., FACC
DIRECTOR
Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.


MyoKardia was bt out by BMS
Kiwi
👍️0
Whalatane Whalatane 5 months ago
RMB. You might look at TNYA also ...similar space. Ceo is one very smart guy and is backed by the Column group ( smart team )
Early days tho .
EWTX is far further along

BOTH are high speculative ...so.....etc
Kiwi
👍️0
rosemountbomber rosemountbomber 5 months ago
Kiwi you have peaked my interest in EWTX

The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.

It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.
👍️0
Whalatane Whalatane 5 months ago
EWTX. Best Co I've seen in this area since MYOK ...which was eventually bt out .
Kiwi
👍️0
Whalatane Whalatane 5 months ago
Impressive presentation at JPM 2024 . Fast tracked but the earliest they are likely to have an approved drug is early 2026...if all goes well
Kiwi
👍️0
goodfree goodfree 3 years ago
Looks like we may have hit the bottom lol
👍️0
goodfree goodfree 3 years ago
Jumped in at $30 today hope we have a good run here
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The Company is principally focused on discovering, developing and commercializing treatments for rare muscle disorders. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The Company's lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company's research programs include EDG-6289, EDG-002 and EDG-003.
👍️0

Your Recent History

Delayed Upgrade Clock